Abstract
Program Description:
Evaluation of thyroid nodules with surgeon-performed ultrasound and fine-needle aspiration (FNA), armed with molecular testing, is rapidly transforming thyroid surgery. Didactic presentations and case studies including American Thyroid Association (ATA) guidelines will provide participants with risk stratification using ultrasound and pearls for surgeon-performed FNA. Molecular Classifiers have a 95% negative predictive value for indeterminate nodules reducing unnecessary diagnostic lobectomies. Molecular alteration testing from FNA with panels including BRAF is 100% specific for papillary thyroid cancer and has evolved into next-generation sequencing from the cancer genome atlas (TCGA). Combined mutation marker analysis has improved prognostic information. Personalized thyroid cancer surgical management is approaching.
Educational Objectives:
(1) Explain that Molecular Classifier testing for cytologically indeterminate nodules may reduce the number of unnecessary diagnostic thyroid lobectomies. (2) Recognize next-generation sequencing and the cancer genome atlas for cytologically indeterminate nodules will improve the diagnosis of thyroid cancer. (3) Interpret ATA guidelines for ultrasound, FNA, molecular testing, and prognostication.
Get full access to this article
View all access options for this article.